Ewing Sarcoma | CHOP Research Institute

Ewing Sarcoma

This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory").

Published on
Mar 5, 2024
Two global teams are developing solid cancer drugs and understanding T-cell receptors.
Published on
Oct 11, 2023
The Center for Precision Medicine for High-risk Pediatric Cancer Frontier Program builds upon ongoing precision medicine efforts across CHOP departments to define and expand treatment options.
Published on
Sep 22, 2023
Dr. Patrick Grohar will lead a research team to bring new therapies to clinical trial.

The Grohar Laboratory uses a bench-to-bedside-and-back approach to develop targeted therapies for pediatric solid tumors with a primary focus on the therapeutic targeting of EWS-FLI1 for Ewing sarcoma.

This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy.

This study involves taking a study drug called lurbinectedin.

Dr. Grohar is a pediatric oncologist and physician-scientist focused on the development of novel molecularly targeted therapies for pediatric solid tumors.

groharp [at] chop.edu

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Published on
Nov 30, 2022
The Emerging Innovators at CHOP Research Institute cover a variety of scientific disciplines.